Autonomic Dysfunctions in Parkinson’s Disease: Prevalence, Clinical Characteristics, Potential Diagnostic Markers, and Treatment

Zhang, Zhe; Chen, Shengdi

doi:10.1155/2020/8740732

Cited by 7 publications

(3 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported frequency of symptoms of psychosis and dysautonomic symptoms in our study population is consistent with the literature, where the prevalence of psychosis varies from 16% to 75% 8 , and that of dysautonomia varies from 27% to 87% 15 , depending on the specific manifestations studied and the criteria or scales utilized. In our study, we employed Part I of the MDS-UPDRS scale, which assesses the presence of certain non-motor symptoms over the past week, potentially influencing the reported frequency.…”

Section: Discussionsupporting

confidence: 91%

Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study

Esparza-Hernández,

Garza-Brambila,

Acevedo-Castillo

et al. 2024

RMN

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study

Esparza-Hernández,

Garza-Brambila,

Acevedo-Castillo

et al. 2024

RMN

View full text Add to dashboard Cite

“…Some PD autonomic symptoms, such as constipation, are known to appear a decade earlier than motor symptoms. GIT dysfunction in PD is represented by a broad group of symptoms, such as weight loss, sialorrhea, dysphagia, symptoms of gastroparesis (including anorexia, early satiation, nausea, vomiting, gastric distention, and weight loss), constipation, intestinal dyskinesia, and small intestine bacteria overgrowth (SIBO) [ 15 , 16 ]. The negative influence of gastrointestinal dysfunction and its symptoms on the total QoL was found at early stages of PD.…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage

Пилипович

Воробьева

Makarov

et al. 2022

Parkinson's Disease

View full text Add to dashboard Cite

Background. There are still no clearly proven methods to slow down or stop the progression of Parkinson’s disease (PD). Thus, improving the quality of life (QoL) of patients with PD becomes of primary importance. Autonomic dysfunction and its symptoms are known to worsen the quality of life in PD, but the degree of this influence is underinvestigated. Particularly, impacts of the separate significant gastrointestinal symptoms, such as dyspepsia, constipation, and abdominal pain, in PD should be more precisely evaluated with the help of specific scales. Objective. To assess the impacts of gastrointestinal dysfunction and its symptoms on PD patient’s QoL using PDQ-39. Methods. 111 PD patients in the I-III Hoehn and Yahr (H&Y) stage were enrolled in the study. The following scales were applied: UPDRS III, PDQ-39, GSRS, GDSS, MMSE, BDI, STAI-S, and STAI-T. Results. The linear regression model showed that the PDQ-39 SI depended on summary assessments GSRS-SI (β = 0.333, p < 0.001 ), BDI (β = 0.463, p < 0.001 ), and UPDRS III (β = 0.163, p < 0.05 ). The use of the stepwise method, adding GSRS-SI and UPDRS III scores to the BDI predictor, improved the model (R2 increased from 0.454 to 0.574). The investigation of GSRS domain’s influence revealed that PDQ-39 SI had a significant correlation with almost all of them, but the regression analysis showed significant QoL impacts of only two factors: constipation and abdominal pain (β = 0.288, p < 0.01 and β = 0.243, p < 0.05 accordingly). Conclusions. Our results suggest a considerable negative influence of depression and gastrointestinal dysfunction (especially constipation and abdominal pain) on QoL of patients with PD. Their impact on QoL in patients with I-III H&Y stages of PD is more significant than that of motor symptoms. Therefore, the correction of depression and gastrointestinal dysfunction should be prioritized in PD therapy.

show abstract

“…Autonomic disorders and cardiovascular abnormalities are among the most common non-motor symptoms of PD ( Scorza et al, 2018 ; Park et al, 2020 ; Cuenca-Bermejo et al, 2021 ). It is expected that about 80%–90% of PD patients will have changes in the autonomic system, and a higher risk of dying due to major cardiac complications than the general population ( Palma and Kaufmann, 2018 ; Scorza et al, 2018 ; Zhang and Chen, 2020 ; Gonçalves et al, 2021 ). Likewise, there is twice the prevalence of heart failure in patients with PD compared to the general population ( Cuenca-Bermejo et al, 2021 ), and these patients are more susceptible to heart failure, coronary artery disease, sudden cardiac death, orthostatic hypotension, hypertension, bradycardia and reduced heart rate variability, pointing to direct changes in the sympathetic and parasympathetic nervous systems ( Gonçalves et al, 2020 ; Finsterer et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Propolis induces cardiac metabolism changes in 6-hydroxydopamine animal model: A dietary intervention as a potential cardioprotective approach in Parkinson’s disease

et al. 2022

View full text Add to dashboard Cite

While there is sustained growth of the older population worldwide, ageing is a consistent risk factor for neurodegenerative diseases, such as Parkinson’s-disease (PD). Considered an emblematic movement disorder, PD comprises a miscellany of non-motor symptoms, for which effective management remains an unfulfilled need in clinical practice. Highlighted are the cardiovascular abnormalities, that cause significant burden in PD patients. Evidence suggests that key biological processes underlying PD pathophysiology can be modulated by diet-derived bioactive compounds, such as green propolis, a natural functional food with biological and pharmacological properties. The effects of propolis on cardiac affection associated to PD have received little coverage. In this study, a metabolomics approach and Positron Emission Tomography (PET) imaging were used to assess the metabolic response to diet supplementation with green propolis on heart outcomes of rats with Parkinsonism induced by 6-hydroxydopamine (6-OHDA rats). Untargeted metabolomics approach revealed four cardiac metabolites (2-hydroxybutyric acid, 3-hydroxybutyric acid, monoacylglycerol and alanine) that were significantly modified between animal groups (6-OHDA, 6-OHDA + Propolis and sham). Propolis-induced changes in the level of these cardiac metabolites suggest beneficial effects of diet intervention. From the metabolites affected, functional analysis identified changes in propanoate metabolism (a key carbohydrate metabolism related metabolic pathway), glucose-alanine cycle, protein and fatty acid biosynthesis, energy metabolism, glutathione metabolism and urea cycle. PET imaging detected higher glucose metabolism in the 17 areas of the left ventricle of all rats treated with propolis, substantially contrasting from those rats that did not consume propolis. Our results bring new insights into cardiac metabolic substrates and pathways involved in the mechanisms of the effects of propolis in experimental PD and provide potential novel targets for research in the quest for future therapeutic strategies.

show abstract

Autonomic Dysfunctions in Parkinson’s Disease: Prevalence, Clinical Characteristics, Potential Diagnostic Markers, and Treatment

Cited by 7 publications

References 104 publications

Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study

Factors associated with psychotic symptoms in ParkinsonÓ?s disease: a cross-sectional study

Gastrointestinal Dysfunction Impact on Life Quality in a Cohort of Russian Patients with Parkinson’s Disease I-III H&Y Stage

Propolis induces cardiac metabolism changes in 6-hydroxydopamine animal model: A dietary intervention as a potential cardioprotective approach in Parkinson’s disease

Contact Info

Product

Resources

About